The sex hormone estradiol (E2) appears to mediate both anti-atherogenic and pro-inflammatory effects in premenopausal women, suggesting a complex immunomodulatory role. Tumor necrosis factor (TNF) is a key pro-inflammatory cytokine involved in the pathogenesis of atherosclerosis and other inflammatory diseases. Alterations at the TNF receptors (TNFRs) and their downstream signaling/transcriptional pathways can affect inflammatory responses. Given this background, we hypothesized that chronic E2 exposure would alter endothelial inflammatory response involving modulation at the levels of TNFRs and signaling pathways. HUVECs were used as the model system. Pre-treatment with E2 did not significantly alter TNF-induced upregulation of pro-inflammatory molecules ICAM-1 (3–6 times) and VCAM-1 (5–7 times). However, pharmacological inhibition of transcriptional pathways suggested a partial shift from NF-ĸB (from 97 to 64%) towards the JNK/AP-1 pathway in ICAM-1 upregulation on E2 treatment. In contrast, VCAM-1 expression remained NF-ĸB dependent in both control (∼96%) and E2 treated (∼85%) cells. The pro-inflammatory TNF effects were mediated by TNFR1. Interestingly, E2 pre-treatment increased TNFR2 levels in these cells. Concomitant TNFR2 activation (but not TNFR1 activation alone) led to the shift towards JNK/AP-1-mediated ICAM-1 upregulation in E2-treated cells, suggesting the effects of chronic E2 to be dependent on TNFR2 signaling.

1.
Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C: World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002;106:1602–1605.
2.
Lopez AD, Mathers CD: Measuring the global burden of disease and epidemiological transitions: 2002–2030. Ann Trop Med Parasitol 2006;100:481–499.
3.
Stork S, van der Schouw YT, Grobbee DE, Bots ML: Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab 2004;15:66–72.
4.
Regitz-Zagrosek V: Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 2006;5:425–438.
5.
Qiao X, McConnell KR, Khalil RA: Sex steroids and vascular responses in hypertension and aging. Gend Med 2008;5(suppl A):S46–S64.
6.
Arnal JF, Scarabin PY, Tremollieres F, Laurell H, Gourdy P: Estrogens in vascular biology and disease: where do we stand today? Curr Opin Lipidol 2007;18:554–560.
7.
Oliver JE, Silman AJ: Why are women predisposed to autoimmune rheumatic diseases? Arthritis Res Ther 2009;11:252.
8.
Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS: Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257–268.
9.
Masi AT, Aldag JC, Chatterton RT: Sex hormones and risks of rheumatoid arthritis and developmental or environmental influences. Ann NY Acad Sci 2006;1069:223–235.
10.
Masi AT, Kaslow RA: Sex effects in systemic lupus erythematosus: a clue to pathogenesis. Arthritis Rheum 1978;21:480–484.
11.
Lahita RG: The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999;11:352–356.
12.
Lahita RG: Sex steroids and SLE: metabolism of androgens to estrogens. Lupus 1992;1:125–127.
13.
Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF: The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007;48:751–762.
14.
Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J: Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:373–379.
15.
Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, Maini RN: Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:38–47.
16.
Blankenberg S, Barbaux S, Tiret L: Adhesion molecules and atherosclerosis. Atherosclerosis 2003;170:191–203.
17.
Foster CA: VCAM-1/alpha 4-integrin adhesion pathway: therapeutic target for allergic inflammatory disorders. J Allergy Clin Immunol 1996;98:S270–S277.
18.
Rahman A, Fazal F: Hug tightly and say goodbye: role of endothelial ICAM-1 in leukocyte transmigration. Antioxid Redox Signal 2009;11:823–839.
19.
Caulin-Glaser T, Watson CA, Pardi R, Bender JR: Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996;98:36–42.
20.
Florian M, Florianova L, Hussain S, Magder S: Interaction of estrogen and tumor necrosis factor alpha in endothelial cell migration and early stage of angiogenesis. Endothelium 2008;15:265–275.
21.
Florian M, Magder S: Estrogen decreases TNF-alpha and oxidized LDL induced apoptosis in endothelial cells. Steroids 2008;73:47–58.
22.
Zhang X, Wang LY, Jiang TY, Zhang HP, Dou Y, Zhao JH, Zhao H, Qiao ZD, Qiao JT: Effects of testosterone and 17-beta-estradiol on TNF-alpha-induced E-selectin and VCAM-1 expression in endothelial cells. Analysis of the underlying receptor pathways. Life Sci 2002;71:15–29.
23.
Zhang X, Wang L, Dou Y, Zhao J, Jiang T, Qiao Z, Qiao J: Testosterone and estradiol modulate TNF-alpha-induced expression of adhesion molecules in endothelial cells. Methods Find Exp Clin Pharmacol 2002;24:125–130.
24.
Aziz KE, Wakefield D: Modulation of endothelial cell expression of ICAM-1, E-selectin, and VCAM-1 by beta-estradiol, progesterone, and dexamethasone. Cell Immunol 1996;167:79–85.
25.
Al-Lamki RS, Wang J, Vandenabeele P, Bradley JA, Thiru S, Luo D, Min W, Pober JS, Bradley JR: TNFR1- and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J 2005;19:1637–1645.
26.
McFarlane SM, Pashmi G, Connell MC, Littlejohn AF, Tucker SJ, Vandenabeele P, MacEwan DJ: Differential activation of nuclear factor-kappaB by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorly. FEBS Lett 2002;515:119–126.
27.
Ferrero E, Zocchi MR, Magni E, Panzeri MC, Curnis F, Rugarli C, Ferrero ME, Corti A: Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability. Am J Physiol Cell Physiol 2001;281:C1173–C1179.
28.
Al-Lamki RS, Brookes AP, Wang J, Reid MJ, Parameshwar J, Goddard MJ, Tellides G, Wan T, Min W, Pober JS, Bradley JR: TNF receptors differentially signal and are differentially expressed and regulated in the human heart. Am J Transplant 2009;9:2679–2696.
29.
Pan S, An P, Zhang R, He X, Yin G, Min W: Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol 2002;22:7512–7523.
30.
Ahn KS, Aggarwal BB: Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann NY Acad Sci 2005;1056:218–233.
31.
Wu L, Juurlink BH: Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 2002;39:809–814.
32.
Chen G, Goeddel DV: TNF-R1 signaling: a beautiful pathway. Science 2002;296:1634–1635.
33.
Varfolomeev EE, Ashkenazi A: Tumor necrosis factor: an apoptosis JuNKie? Cell 2004;116:491–497.
34.
Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781–25790.
35.
Anderson HD, Rahmutula D, Gardner DG: Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem 2004;279:963–969.
36.
Moon SO, Kim W, Sung MJ, Lee S, Kang KP, Kim DH, Lee SY, So JN, Park SK: Resveratrol suppresses tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells. Mol Pharmacol 2006;70:112–119.
37.
Sfikakis PP, Tsokos GC: Towards the next generation of anti-TNF drugs. Clin Immunol 2011;141:231–235.
38.
Yui J, Hemmings D, Garcia-Lloret M, Guilbert LJ: Expression of the human p55 and p75 tumor necrosis factor receptors in primary villous trophoblasts and their role in cytotoxic signal transduction. Biol Reprod 1996;55:400–409.
39.
Zhou Z, Connell MC, MacEwan DJ: TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells. Cell Signal 2007;19:1238–1248.
40.
Sankaralingam S, Xu Y, Sawamura T, Davidge ST: Increased lectin-like oxidized low-density lipoprotein receptor-1 expression in the maternal vasculature of women with preeclampsia: role for peroxynitrite. Hypertension 2009;53:270–277.
41.
Merchant SJ, Narumiya H, Zhang Y, Guilbert LJ, Davidge ST: The effects of preeclampsia and oxygen environment on endothelial release of matrix metalloproteinase-2. Hypertens Pregnancy 2004;23:47–60.
42.
Arenas IA, Xu Y, Lopez-Jaramillo P, Davidge ST: Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol 2004;286:C779–C784.
43.
Narumiya H, Zhang Y, Fernandez-Patron C, Guilbert LJ, Davidge ST: Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy 2001;20:185–194.
44.
Chakrabarti S, Davidge ST: High glucose-induced oxidative stress alters estrogen effects on ERalpha and ERbeta in human endothelial cells: reversal by AMPK activator. J Steroid Biochem Mol Biol 2009;117:99–106.
45.
Chakrabarti A, Sadler AJ, Kar N, Young HA, Silverman RH, Williams BR: Protein kinase R-dependent regulation of interleukin-10 in response to double-stranded RNA. J Biol Chem 2008;283:25132–25139.
46.
Qiu Z, Norflus F, Singh B, Swindell MK, Buzescu R, Bejarano M, Chopra R, Zucker B, Benn CL, DiRocco DP, Cha JH, Ferrante RJ, Hersch SM: Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J Biol Chem 2006;281:16672–16680.
47.
Fu YQ, Fang F, Lu ZY, Kuang FW, Xu F: N-acetylcysteine protects alveolar epithelial cells from hydrogen peroxide-induced apoptosis through scavenging reactive oxygen species and suppressing c-Jun N-terminal kinase. Exp Lung Res 2010;36:352–361.
48.
Kuldo JM, Westra J, Asgeirsdottir SA, Kok RJ, Oosterhuis K, Rots MG, Schouten JP, Limburg PC, Molema G: Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol 2005;289:C1229–C1239.
49.
Goua M, Mulgrew S, Frank J, Rees D, Sneddon AA, Wahle KW: Regulation of adhesion molecule expression in human endothelial and smooth muscle cells by omega-3 fatty acids and conjugated linoleic acids: involvement of the transcription factor NF-kappaB? Prostaglandins Leukot Essent Fatty Acids 2008;78:33–43.
50.
Lopez-Bojorquez LN, Arechavaleta-Velasco F, Vadillo-Ortega F, Montes-Sanchez D, Ventura-Gallegos JL, Zentella-Dehesa A: NF-kappaB translocation and endothelial cell activation is potentiated by macrophage-released signals co-secreted with TNF-alpha and IL-1beta. Inflamm Res 2004;53:567–575.
51.
Ahn KS, Sethi G, Aggarwal BB: Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J Immunol 2007;178:2507–2516.
52.
Mukhopadhyay A, Shishodia S, Suttles J, Brittingham K, Lamothe B, Nimmanapalli R, Bhalla KN, Aggarwal BB: Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors. J Biol Chem 2002;277:30622–30628.
53.
Huang W, Chakrabarti S, Majumder K, Jiang Y, Davidge ST, Wu J: Egg-derived peptide IRWinhibits TNF-alpha-induced inflammatory response and oxidative stress in endothelial cells. J Agric Food Chem 2010;58:10840–10846.
54.
Luo D, Luo Y, He Y, Zhang H, Zhang R, Li X, Dobrucki WL, Sinusas AJ, Sessa WC, Min W: Differential functions of tumor necrosis factor receptor 1 and 2 signaling in ischemia-mediated arteriogenesis and angiogenesis. Am J Pathol 2006;169:1886–1898.
55.
Zen K, Karsan A, Stempien-Otero A, Yee E, Tupper J, Li X, Eunson T, Kay MA, Wilson CB, Winn RK, Harlan JM: NF-kappaB activation is required for human endothelial survival during exposure to tumor necrosis factor-alpha but not to interleukin-1beta or lipopolysaccharide. J Biol Chem 1999;274:28808–28815.
56.
May MJ, Wheeler-Jones CP, Pearson JD: Effects of protein tyrosine kinase inhibitors on cytokine-induced adhesion molecule expression by human umbilical vein endothelial cells. Br J Pharmacol 1996;118:1761–1771.
57.
Hwa JS, Mun L, Kim HJ, Seo HG, Lee JH, Kwak JH, Lee DU, Chang KC: Genipin selectively inhibits TNF-alpha-activated VCAM-1 but not ICAM-1 expression by upregulation of PPAR-gamma in human endothelial cells. Korean J Physiol Pharmacol 2011;15:157–162.
58.
Chakrabarti S, Chan CK, Jiang Y, Davidge ST: Neuronal nitric oxide synthase regulates endothelial inflammation. J Leukoc Biol 2012;91:947–956.
59.
Zen K, Karsan A, Eunson T, Yee E, Harlan JM: Lipopolysaccharide-induced NF-kappaB activation in human endothelial cells involves degradation of IkappaBalpha but not IkappaBbeta. Exp Cell Res 1998;243:425–433.
60.
Laskov R, Berger N, Horwitz MS: Differential effects of tumor necrosis factor-alpha and CD40L on NF-kappa B inhibitory proteins I kappa B alpha, beta and epsilon and on the induction of the Jun amino-terminal kinase pathway in Ramos Burkitt lymphoma cells. Eur Cytokine Netw 2005;16:267–276.
61.
Cheshire JL, Baldwin AS Jr: Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta degradation. Mol Cell Biol 1997;17:6746–6754.
62.
Bates PW, Miyamoto S: Expanded nuclear roles for IkappaBs. Sci STKE 2004;2004:pe48.
63.
Haudek SB, Bryant DD, Giroir BP: Differential regulation of myocardial NF kappa B following acute or chronic TNF-alpha exposure. J Mol Cell Cardiol 2001;33:1263–1271.
64.
Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, Li Z, Evans DB, Abbruzzese JL, Chiao PJ: NF-kappaB and AP- 1 connection: mechanism of NF-kappaB- dependent regulation of AP-1 activity. Mol Cell Biol 2004;24:7806–7819.
65.
Schmidt C, Peng B, Li Z, Sclabas GM, Fujioka S, Niu J, Schmidt-Supprian M, Evans DB, Abbruzzese JL, Chiao PJ: Mechanisms of proinflammatory cytokine-induced biphasic NF-kappaB activation. Mol Cell 2003;12:1287–1300.
66.
Rao P, Hayden MS, Long M, Scott ML, West AP, Zhang D, Oeckinghaus A, Lynch C, Hoffmann A, Baltimore D, Ghosh S: IkappaBbeta acts to inhibit and activate gene expression during the inflammatory response. Nature 2010;466:1115–1119.
67.
Zhang R, Xu Y, Ekman N, Wu Z, Wu J, Alitalo K, Min W: Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem 2003;278:51267–51276.
68.
Goukassian DA, Qin G, Dolan C, Murayama T, Silver M, Curry C, Eaton E, Luedemann C, Ma H, Asahara T, Zak V, Mehta S, Burg A, Thorne T, Kishore R, Losordo DW: Tumor necrosis factor-alpha receptor p75 is required in ischemia-induced neovascularization. Circulation 2007;115:752–762.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.